Cato BioVentures will Attend the 18th Annual BIO-Europe 2012 Conference and Host a Wine Tasting at One of their Offices in Germany

Experts from Cato BioVentures are attending Europe’s largest partnering conference, the 18th annual BIO-Europe 2012 conference in Hamburg, Germany, this week. This global, biotechnology conference is expected to be well attended by leaders and dealmakers from all sectors of the industry, including biotechnology, pharmaceuticals, and finance, along with many emerging companies.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Cato BioVentures

DURHAM, NC (PRWEB) November 12, 2012

Experts from Cato BioVentures are attending Europe’s largest partnering conference, the 18th annual BIO-Europe 2012 conference in Hamburg, Germany, this week. This global, biotechnology conference is expected to be well attended by leaders and dealmakers from all sectors of the industry, including biotechnology, pharmaceuticals, and finance, along with many emerging companies.

Attending experts, Jo Cato, Ph.D., Vice President of Cato BioVentures and Chief Operating Officer of Cato Research; and Margaretha (Marga) Oortgiesen, Ph.D., R.A.C., C.C.R.P., Analyst of Cato BioVentures and Senior Vice President of Drug Development of Cato Research will join the conference in one-on-one partnering meetings and gain further insight into the biotechnology industry by participating in workshops.

As a closing reception for visiting partners and guests on Thursday, 15 November, from 17:30 to 20:30, Cato BioVentures will host an informal wine tasting at its local office in Cologne, Germany.

For more information or to attend this event, please visit:
http://www.cato.com/marketing/2012/Wine-Tasting_Germany2012.html

About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success.

About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost effectiveness. For more information about Cato Research, visit http://www.cato.com.

For more information about Cato BioVentures or the wine tasting, please contact:
Cato BioVentures
Phone: 919-361-2286
http://www.catobioventures.com

# # #


Contact

Follow us on: Contact's Twitter